<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04881760</url>
  </required_header>
  <id_info>
    <org_study_id>18122</org_study_id>
    <secondary_id>J1I-MC-GZBF</secondary_id>
    <nct_id>NCT04881760</nct_id>
  </id_info>
  <brief_title>A Study of LY3437943 in Participants Who Have Obesity or Are Overweight</brief_title>
  <official_title>A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of LY3437943 in participants who have obesity or are overweight. The main&#xD;
      purpose is to learn more about how LY3437943 affects body weight loss. The study will last&#xD;
      about 18 months and may include up to 18 visits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">November 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 17, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Change in Body Weight</measure>
    <time_frame>Randomization, Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in Body Weight</measure>
    <time_frame>Randomization, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve ≥5% Body Weight Reduction</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve ≥5% Body Weight Reduction</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve ≥10% Body Weight Reduction</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve ≥10% Body Weight Reduction</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve ≥15% Body Weight Reduction</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve ≥15% Body Weight Reduction</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Body Weight</measure>
    <time_frame>Randomization, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Body Weight</measure>
    <time_frame>Randomization, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Body Mass Index (BMI)</measure>
    <time_frame>Randomization, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in BMI</measure>
    <time_frame>Randomization, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Waist Circumference</measure>
    <time_frame>Randomization, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Randomization in Waist Circumference</measure>
    <time_frame>Randomization, Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">494</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>LY3437943 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3437943 administered subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3437943 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3437943 administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3437943 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3437943 administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3437943 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3437943 administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3437943</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3437943 Dose 1</arm_group_label>
    <arm_group_label>LY3437943 Dose 2</arm_group_label>
    <arm_group_label>LY3437943 Dose 3</arm_group_label>
    <arm_group_label>LY3437943 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have a Body Mass Index (BMI) ) ≥30 and ≤50 kilograms per square&#xD;
             meter (kg/m²), or ≥27 kg/m² and &lt;30 kg/m², with at least one of the following&#xD;
             comorbidities: hypertension, dyslipidemia, cardiovascular disease&#xD;
&#xD;
          -  Participants must be willing to learn how to self-inject study drug or receive an&#xD;
             injection from a trained individual if visually impaired or with physical limitations,&#xD;
             and follow study procedures for the duration of the study, including, but not limited&#xD;
             to, follow lifestyle advice (for example, dietary changes and physical activity plan),&#xD;
             maintain a study drug administration log, and complete required questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants must not have type 1 or type 2 diabetes mellitus&#xD;
&#xD;
          -  Participants must not have had an increase or decrease in body weight &gt; more than 5 kg&#xD;
             (11 pounds) within the past 3 months&#xD;
&#xD;
          -  Participants must not have had surgery for obesity or plan to have such surgery during&#xD;
             the study&#xD;
&#xD;
          -  Participants must not be using medications that promote weight loss or cause weight&#xD;
             gain&#xD;
&#xD;
          -  Participants must not drink excessive amounts of alcohol (more than 14 units a week&#xD;
             for women or more than 21 units a week for men)&#xD;
&#xD;
          -  Participants must not have used marijuana within the last 3 months.&#xD;
&#xD;
          -  Participants must not have heart attack, stroke, or hospitalization for congestive&#xD;
             heart failure in the past 3 months&#xD;
&#xD;
          -  Participants must not have active cancer within the last 5 years&#xD;
&#xD;
          -  Participants must not have uncontrolled high blood pressure&#xD;
&#xD;
          -  Participants must not have liver disease other than non-alcoholic fatty liver disease&#xD;
&#xD;
          -  Participants must not have renal impairment with estimated glomerular filtration rate&#xD;
             (eGFR) &lt;45 mL/min/1.73 m2&#xD;
&#xD;
          -  Participants must not have a history of acute or chronic pancreatitis symptomatic&#xD;
             gallbladder disease or documented human immunodeficiency virus infection&#xD;
&#xD;
          -  Participants must not have a major problem with depression or other mental illness&#xD;
             within the last 2 years&#xD;
&#xD;
          -  Participants must not have family or personal history of multiple endocrine neoplasia&#xD;
             type 2 or medullary thyroid carcinoma (family is defined as a first degree relative)&#xD;
&#xD;
          -  Female participants must not be pregnant, breast-feeding, or intend to become pregnant&#xD;
             or of childbearing potential and not using adequate contraceptive method (adequate&#xD;
             contraceptive measures as required by local regulation or practice)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559)</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Perseverance Research Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85254</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>480-471-6132</phone>
    </contact>
    <investigator>
      <last_name>Andrea Kessler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7147747777</phone>
    </contact>
    <investigator>
      <last_name>Amina Zakaria Haggag</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Research</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>5592610992</phone>
    </contact>
    <investigator>
      <last_name>Paul Carlton Norwood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Huntington Park</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>323-588-1968</phone>
    </contact>
    <investigator>
      <last_name>Stanley H. Hsia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Huntington Park</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>2134132500</phone>
    </contact>
    <investigator>
      <last_name>Juan Pablo Frias</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern California Dermatology, Inc.</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-474-2173</phone>
    </contact>
    <investigator>
      <last_name>Wayne Ho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Metabolic Research Centre</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>805-658-8460</phone>
    </contact>
    <investigator>
      <last_name>Ronald Chochinov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Helen L Stacey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>203-785-7421</phone>
    </contact>
    <investigator>
      <last_name>Ania M. Jastreboff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Coast Institute for Research at The Jones Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>904-854-1354</phone>
    </contact>
    <investigator>
      <last_name>Mae Sheikh-Ali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research, Inc.</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>727-849-4131</phone>
    </contact>
    <investigator>
      <last_name>Cathy Barnes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Encore Medical Research - Weston</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>954-400-1725</phone>
    </contact>
    <investigator>
      <last_name>Sandro Bacchelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Springfield Diabetes &amp; Endocrine Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>504-938-8424</phone>
    </contact>
    <investigator>
      <last_name>Diana Widicus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Diabetes and Endocrinology Center</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>785-368-0491</phone>
    </contact>
    <investigator>
      <last_name>susan brian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tandem Clinical Research,LLC</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>504-938-8424</phone>
    </contact>
    <investigator>
      <last_name>Adil Fatakia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>StudyMetrix Research</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>636-387-5100</phone>
    </contact>
    <investigator>
      <last_name>Timothy R Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Palm Research Center Tenaya</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>702-826-2795</phone>
    </contact>
    <investigator>
      <last_name>Samer Nakhle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amici Clinical Research LLC</name>
      <address>
        <city>Raritan</city>
        <state>New Jersey</state>
        <zip>08869</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>732-369-3480</phone>
    </contact>
    <investigator>
      <last_name>Lisa Malak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intend Research, LLC</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>405-701-8999</phone>
    </contact>
    <investigator>
      <last_name>Lisa Connery</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Endocrinology Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>412-359-3426</phone>
    </contact>
    <investigator>
      <last_name>Murray B Gordon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Phase Research and Development</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>865-200-8364</phone>
    </contact>
    <investigator>
      <last_name>Evelyne M Davidson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes &amp; Endocrinology, P.A.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>512-334-3505</phone>
    </contact>
    <investigator>
      <last_name>Valerie D Espinosa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972-566-7799</phone>
    </contact>
    <investigator>
      <last_name>Julio Rosenstock</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juno Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-779-5494</phone>
    </contact>
    <investigator>
      <last_name>Rocio A Harbison</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrine Ips, Pllc</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-973-3415</phone>
    </contact>
    <investigator>
      <last_name>Amer S Al-Karadsheh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Endocrinology Associates</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75149</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>214-693-0904</phone>
    </contact>
    <investigator>
      <last_name>Sumana Gangi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>425-251-1720</phone>
    </contact>
    <investigator>
      <last_name>Leslie J Klaff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice - Dr. Paola Mansilla-Letelier</name>
      <address>
        <city>Guaynabo</city>
        <zip>970</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>787400-0333</phone>
    </contact>
    <investigator>
      <last_name>Paola Mansilla-Letelier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GCM Medical Group, PSC - Hato Rey Site</name>
      <address>
        <city>San Juan</city>
        <zip>00917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7877268396</phone>
    </contact>
    <investigator>
      <last_name>Gregorio A. Cortes-Maisonet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Juan City Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7877643083</phone>
    </contact>
    <investigator>
      <last_name>Michelle Mangual</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/36s0UdwlFjVCXwfbif2fkc</url>
    <description>A Study of LY3437943 in Participants Who Have Obesity or Are Overweight</description>
  </link>
  <verification_date>November 15, 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nutritional or Metabolism Disorder</keyword>
  <keyword>Weight Loss</keyword>
  <keyword>Overnutrition</keyword>
  <keyword>Incretins</keyword>
  <keyword>Hormones</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

